Open-sourcing innovative drug development in neuropsychiatry
Our mission is to advance psychiatry using open-source principles.
Elata's model aims to serve all contributors
For investors
It is no secret that drug development is a pricey endeavor, and it is no surprise that private markets are generally uninterested in investing in projects with low upside potential. Elata fixes this by providing high upside potential and ROI through issuing an allocation of royalty streams and cashflows stemming from drug sales and licensing agreements amongst tokenholders.
For researchers
Elata is forming a psychiatric innovation unit to advance novel compound research, inviting pioneering researchers to steer early-stage drug development.
Elata aims to unify the psychiatric research community, enhancing collaboration and aligning incentives through a community-focused approach.
For patients
Developing an open community that patients can use is the key and most important part of Elata.
We prioritize patient outcomes by fostering an open community, ensuring that scientific advancements and funding interests align closely with the needs of patients.